Yi Xiao Jiang

Dr. Yi Xiao Jiang

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2025 in Nature
Verified
Journal Article
Closed access
PDF file
-H- Hou
- Hou
PGPeng Ge
Peng Ge
MSMichael R. Sawaya
Michael R. Sawaya
LLLiisa Lutter
Liisa Lutter
JDJoshua L. Dolinsky
Joshua L. Dolinsky
DEDavid S. Eisenberg
David S. Eisenberg

25 April 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
ETEinav Tayeb-Fligelman
Einav Tayeb-Fligelman
JBJeannette T. Bowler
Jeannette T. Bowler
CTChristen E. Tai
Christen E. Tai
MSMichael R. Sawaya
Michael R. Sawaya
YJYi Xiao Jiang
Yi Xiao Jiang
DEDavid S. Eisenberg
David S. Eisenberg
The self-assembly of the Nucleocapsid protein (NCAP) of SARS-CoV-2 is crucial for its function. Computational analysis of the amino acid sequence of NCAP reveals low-complexity domains (LCDs) akin to LCDs in other proteins known to self-assemble as phase separation droplets and amyloid fibrils. Previous reports have described NCAP’s propensity to phase-separate. Here we show that the central LCD of NCAP is capable of both, phase separation and amyloid formation. Within this central LCD we identified three adhesive segments and determined the atomic structure of the fibrils formed by each. Those structures guided the design of G12, a peptide that interferes with the self-assembly of NCAP and demonstrates antiviral activity in SARS-CoV-2 infected cells. Our work, therefore, demonstrates the amyloid form of the central LCD of NCAP and suggests that amyloidogenic segments of NCAP could be targeted for drug development.

30 July 2025 in Journal of Molecular Biology
Verified
Journal Article
Open access
YJYi Xiao Jiang
Yi Xiao Jiang
DEDavid S. Eisenberg
David S. Eisenberg
For half a century, Anfinsen's Thermodynamic Hypothesis has been considered the central pillar of protein science. In Anfinsen's words, this hypothesis holds that "…the three-dimensional structure of a native protein in its normal physiological milieu…is the one in which the Gibbs free energy of the whole system is lowest; that is, that the native conformation is determined by the totality of interatomic interactions and hence by the amino acid sequence, in a given environment". Applying this hypothesis to amyloid fibril-forming proteins presents challenges, which we contemplate in four questions. First, what is the "native" structure of amyloid-forming proteins, many which are intrinsically disordered or are proteolytic fragments of larger proteins? Second, what is the thermodynamic landscape for the conversion of native monomers to highly stable fibril assemblies? Third, how do we reconcile Anfinsen's hypothesis, that a protein's amino acid sequence determines its 3-dimensional structure, with amyloid fibrils, for which single protein sequences are capable of folding into multiple polymorphs? Fourth, what is the "physiological milieu" of amyloid fibrils? Is it increased local concentration, cofactor binding, post-translational modifications, or cellular programming of diseased tissues? We discuss answers supplied by ex vivo observations and in vitro experiments, and conclude that amyloid protein structure in vivo is determined by its sequence and its physiological milieu.

26 March 2026 in iScience
Verified
Journal Article
Open access
RARomany Abskharon
Romany Abskharon
YJYi Xiao Jiang
Yi Xiao Jiang
MSMichael R. Sawaya
Michael R. Sawaya
PGPeng Ge
Peng Ge
JZJeffrey Zhang
Jeffrey Zhang
DEDavid S. Eisenberg
David S. Eisenberg
RNA colocalizes with tau deposits in Alzheimer’s disease (AD) and drives tau aggregation in vitro. Previously, we determined a cryogenic-electron microscopy (cryo-EM) structure of fibrils of full-length tau bound to unfractionated mammalian RNA, revealing a small tau C-terminal core. Here, we present the cryo-EM structure of fibrils of full-length recombinant tau bound to unfractionated mammalian RNA seeded by AD-extracted tau fibrils. This structure reveals an expanded tau C-terminal core resembling AD tau fibrils. RNA sequencing identified 18S ribosomal RNA as the primary fibril-bound species. Next, we determined the cryo-EM structure of fibrils of full-length recombinant tau bound to mammalian 18S ribosomal RNA, revealing a core that consists of the R2 to R4 repeat domains previously seen in pathological tau fibrils. All our recombinant RNA-tau fibrils dissolve upon RNase treatment. Tau fibrils adopt distinct folds in the presence of different RNAs, suggesting RNA is a cofactor capable of shaping tau fibril polymorphism.

1 October 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
GRGregory M. Rosenberg
Gregory M. Rosenberg
KMKevin A. Murray
Kevin A. Murray
MSMichael R. Sawaya
Michael R. Sawaya
YJYi Xiao Jiang
Yi Xiao Jiang
Daniel GeschwindDaniel Geschwind
Daniel Geschwind
DEDavid S. Eisenberg
David S. Eisenberg
The conversion of proteins into insoluble fibrillar aggregates known as amyloid occurs in a wide variety of diseases, e.g., Alzheimer’s disease, amyotrophic lateral sclerosis, systemic transthyretin amyloidosis, and multisystem atrophy. There are more than 60 disease-associated amyloid-forming proteins, and amyloid formation can occur sporadically or can be induced or accelerated by genetic mutations. This Review discusses structural mechanisms by which genetic changes promote amyloid formation and thereby influence disease outcomes. By dividing amyloid-forming proteins into six types according to the genetic mutations they carry and analyzing mutation-induced structural changes in amyloid fibrils, a better understanding of inheritance patterns of amyloid diseases (amyloidoses) can be obtained.

8 May 2024 in Research Square
Verified
Preprint
Open access
PDF file
DEDavid Eisenberg
David Eisenberg
-H- Hou
- Hou
PGPeng Ge
Peng Ge
MSMichael Sawaya
Michael Sawaya
JDJoshua Dolinsky
Joshua Dolinsky
JFJuli Feigon
Juli Feigon
Reducing fibrous aggregates of protein tau is a possible strategy for halting progression of Alzheimer's dis-ease (AD). Previously we found that in vitro the D-peptide D-TLKIVWC disassembles tau fibrils from AD brains (AD-tau) into benign segments with no energy source present beyond ambient thermal agitation. This disassembly by a short peptide was unexpected, given that AD-tau is sufficiently stable to withstand disas-sembly in boiling SDS detergent. To consider D peptide-mediated disassembly as a potential therapeutic for AD, it is essential to understand the mechanism and energy source of the disassembly action. We find as-sembly of D-peptides into amyloid-like fibrils is essential for tau fibril disassembly. Cryo-EM and atomic force microscopy reveal that these D-peptide fibrils have a right-handed twist and embrace tau fibrils which have a left-handed twist. In binding to the AD-tau fibril, the oppositely twisted D-peptide fibril produces a strain, which is relieved by the disassembly of both fibrils. This strain-relief mechanism appears to operate in other examples of amyloid fibril disassembly and provides a new direction for the development of first-in-class therapeutics for amyloid diseases.